Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Infectious diseases, microbiology and sexual health indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Penicillin allergy assessment

Infectious diseases, microbiology and sexual health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Current wheeze, hypotension, airway swelling, widespread urticaria or rapidly progressive mucocutaneous blistering after a medicine is an emergency. Stop the suspected drug, treat anaphylaxis through Resuscitation Council UK guidance and obtain urgent specialist help for severe cutaneous reactions.

Purpose and principles

Replace an imprecise penicillin-allergy label with a structured phenotype, distinguish intolerance from immediate or severe delayed hypersensitivity, and select safe testing or antibiotic alternatives.

A penicillin-allergy label is a clinical history that may or may not represent persistent immune hypersensitivity. Many labels originate from childhood viral rashes, predictable adverse effects or remote events that were never characterised. Conversely, severe immediate and delayed reactions can recur with major harm. The assessment therefore seeks a phenotype and risk category, not a binary answer from memory alone.

Timing is crucial. Immediate reactions generally occur soon after exposure and feature urticaria, angio-oedema, bronchospasm or cardiovascular compromise. Delayed maculopapular eruptions differ from severe cutaneous adverse reactions involving mucosa, blistering, systemic symptoms, eosinophilia or organ injury. The exact drug and any later tolerated penicillin or cephalosporin materially change probability.

Testing should answer a prescribing need under a governed protocol. Low-risk histories may be suitable for direct oral challenge in specialist-led services; other immediate phenotypes may need skin testing followed by challenge. Severe delayed syndromes are generally not challenged. A negative supervised evaluation must be translated into visible record changes and patient explanation or the harmful label will return.

Key points

  • Ask which drug was taken, why, route, timing after the dose, symptoms, treatment, hospitalisation, time since reaction and subsequent beta-lactam tolerance.
  • Nausea, diarrhoea, headache, family history or an unknown childhood label is not equivalent to IgE-mediated allergy, although uncertainty still needs safe documentation.
  • Immediate urticaria, angio-oedema, bronchospasm or hypotension suggests an immediate hypersensitivity phenotype; severe blistering, mucosal or organ injury indicates a high-risk delayed reaction.
  • Do not perform an unsupervised test dose. Skin testing and direct oral challenge require a risk-stratified specialist or locally governed pathway with rescue capability.
  • Document the specific culprit and phenotype rather than 'penicillin allergy', and update both prescribing and primary-care records after specialist testing.
  • De-labelling can restore narrower first-line treatment and reduce broad-spectrum exposure, but patient safety and shared understanding take priority over label removal targets.

Indications, selection and cautions

Low-risk non-allergic history

Isolated gastrointestinal upset, headache, family history, an unknown remote label or a non-urticarial rash without systemic features may represent intolerance or low probability.

Immediate hypersensitivity phenotypeRed flag

Rapid urticaria, angio-oedema, wheeze, throat symptoms, hypotension or collapse after a beta-lactam suggests IgE-mediated or other immediate allergy.

Severe delayed phenotypeRed flag

Mucosal involvement, blistering, skin pain, facial oedema, eosinophilia, hepatitis, nephritis or systemic illness suggests a severe cutaneous or organ reaction.

Evidence of later tolerance

Documented subsequent therapeutic exposure to the same penicillin without reaction substantially weakens the original label, provided drug identity and course are reliable.

Method and interpretation

  1. 01
    Structured allergy historyFirst step
    Why
    Classify culprit, timing, symptoms, severity, treatment and subsequent tolerance before choosing any test.
    Interpretation and limitations
    A precise reproducible history can identify intolerance, low-risk rash, immediate reaction or severe delayed disease and prevents inappropriate challenge.
  2. 02
    Medication and primary-care record review
    Why
    Verify drug names, dates, hospital coding and later beta-lactam prescriptions.
    Interpretation and limitations
    Conflicting records are common. Confirm actual administration and tolerance rather than assuming a prescription was taken.
  3. 03
    Specialist skin testing
    Why
    Assess selected immediate-reaction phenotypes using validated reagents and controls.
    Interpretation and limitations
    Negative testing reduces but does not eliminate risk and is commonly followed by supervised challenge; antihistamines and technique affect validity.
  4. 04
    Supervised oral provocation challenge
    Why
    Demonstrate tolerance when risk assessment supports direct or post-skin-test challenge.
    Interpretation and limitations
    Challenge must use a governed setting, observation and emergency readiness. Absence of immediate reaction does not exclude every delayed eruption, so follow-up instructions matter.

Clinical next steps

01History at prescribingCreate a usable phenotypeFirst stepA patient reports penicillin allergy when antibacterial treatment is being considered.+
  1. 1Ask exact drug, indication, dose-to-symptom timing, manifestations, treatment, admission and later tolerated beta-lactams; examine current reaction if present.
  2. 2Classify as likely intolerance, low-risk uncertain, immediate hypersensitivity or severe delayed reaction and record uncertainty explicitly.
  3. 3Choose infection treatment from severity and the phenotype, consulting microbiology when avoiding beta-lactams materially compromises efficacy or spectrum.
02Potential de-labellingRefer to a governed test pathwayA low-risk or uncertain label limits likely future treatment and the patient is clinically suitable for evaluation.+
  1. 1Verify records and exclude pregnancy, unstable asthma, current acute illness or a severe delayed phenotype

Risks, monitoring and follow-up

  • During supervised challenge, record dose time, observations, objective skin or respiratory findings and the observation period specified by the service protocol.
  • Provide delayed-reaction advice after testing and a route to report rash, fever or systemic symptoms emerging after discharge.
  • Reconcile allergy status across hospital prescribing, discharge summary, general-practice record and the patient's own information after evaluation.
  • Audit whether a removed label reappears and whether alternative broad-spectrum antibiotics continue despite documented tolerance.
  • For a current serious reaction, trend airway, circulation, skin and mucosal progression, eosinophils, liver and kidney function and report through MHRA systems.

Special situations

The drug name matters

A reaction to co-amoxiclav could relate to amoxicillin, clavulanate or an unrelated illness; the label should not automatically expand to every antimicrobial.

Cross-reactivity is side-chain dependent

Cephalosporin risk is influenced more by related side chains and phenotype than by the beta-lactam ring alone, requiring medicine-specific assessment.

Negative testing needs communication

A technically successful challenge has little benefit if electronic and primary-care records still block penicillin or the patient believes the allergy persists.

Severe delayed reactions are different

Reassuring statistics about remote childhood rashes must never be applied to SJS/TEN, DRESS or organ-specific immune injury.

Common pitfalls

  1. 01

    Recording 'allergy' without the culprit, timing or symptoms.

  2. 02

    Calling gastrointestinal intolerance an immediate hypersensitivity reaction.

  3. 03

    Giving an unsupervised test dose to a patient with an uncertain history.

  4. 04

    Rechallenging a severe delayed cutaneous reaction.

  5. 05

    Removing a label in one system while leaving contradictory records elsewhere.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Infectious diseases, microbiology and sexual healthOriginal SBA

Low-risk allergy history

A patient labelled penicillin-allergic recalls nausea without rash or breathing difficulty during amoxicillin treatment twenty years ago. What is the best interpretation?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Infectious diseases, microbiology and sexual health topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG183 drug allergyAssessment, documentation, information and specialist referral recommendations.
  • Resuscitation Council UK emergency treatment of anaphylaxisCurrent UK emergency recognition and intramuscular adrenaline guidance.
  • MHRA Yellow Card schemeNational reporting route for suspected serious adverse drug reactions.
  • British Society for Allergy and Clinical ImmunologyUK specialist allergy standards and service resources.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
05
Targeted organ assessment for severe delayed reaction
Why
Identify blood, liver, kidney and skin involvement when DRESS, SJS/TEN or another systemic syndrome is suspected.
Interpretation and limitations
This is diagnostic and safety assessment, not a route to rechallenge. Record implicated and potentially cross-reactive medicines prominently.
according to the testing protocol.
  • 2Use specialist-directed skin testing or direct oral challenge with consent, observation and anaphylaxis capability; never improvise a ward test dose.
  • 3After tolerance, update allergy fields across records, inform the patient and primary care and state exactly which beta-lactams are now considered acceptable.
    • 03Current severe reactionTreat first and preserve evidenceSymptoms suggest anaphylaxis or a severe cutaneous and systemic drug reaction.+
    1. 1Stop the suspected medicine, perform ABCDE and use intramuscular adrenaline promptly for anaphylaxis according to Resuscitation Council UK guidance.
    2. 2Seek emergency dermatology, burns, allergy or critical-care support for mucosal blistering or organ involvement and obtain time-sensitive blood tests.
    3. 3Document culprit, timing and phenotype, report serious reactions through the Yellow Card scheme and arrange specialist follow-up without rechallenge.